Avadel Pharmaceuticals plc today announced the launch of NOCTIVA (desmopressin acetate), an emulsified microdose nasal spray. NOCTIVA was FDA approved in 2017 as a treatment proven to help adults with nocturia due to nocturnal polyuria, a condition which causes the kidneys to overproduce urine at night and prevents people from getting a good night’s sleep.
NOCTIVA’s formulation works in the kidneys to lessen nighttime urine production. The nasal spray is a proprietary emulsified microdose of desmopressin combined with a permeation enhancer that increases the transport of NOCTIVA across the nasal mucosa. Delivered via a unique spray pattern, NOCTIVA’s breakthrough formulation substantially increases the bioavailability of the active drug, allowing for microdosing, rapid absorption, and consistency from dose to dose.
With the NOCTIVA Care+ program available at launch, patients will pay no more than $40 for the prescription. (Terms and conditions apply.)
